IRIS
PASSAMONTI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.744
EU - Europa 1.828
AS - Asia 1.307
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 8
SA - Sud America 5
OC - Oceania 4
Totale 5.906
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.730
CN - Cina 1.185
IE - Irlanda 527
UA - Ucraina 378
FI - Finlandia 274
DE - Germania 204
SE - Svezia 145
IT - Italia 127
GB - Regno Unito 94
SG - Singapore 93
FR - Francia 36
BE - Belgio 17
CA - Canada 13
IN - India 11
MU - Mauritius 7
NL - Olanda 7
RU - Federazione Russa 7
EU - Europa 6
AU - Australia 4
JP - Giappone 4
PL - Polonia 3
RO - Romania 3
TR - Turchia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
CL - Cile 2
CO - Colombia 2
GR - Grecia 2
IR - Iran 2
NG - Nigeria 2
AR - Argentina 1
AZ - Azerbaigian 1
BD - Bangladesh 1
EG - Egitto 1
GE - Georgia 1
HK - Hong Kong 1
HR - Croazia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LT - Lituania 1
LV - Lettonia 1
MX - Messico 1
MY - Malesia 1
NO - Norvegia 1
Totale 5.906
Salva come PNG Salva come JPEG
Città #
Chandler 579
Dublin 527
Jacksonville 469
Nanjing 351
Boardman 196
Ashburn 153
Nanchang 135
Princeton 117
Hebei 116
Lawrence 112
Shenyang 109
Wilmington 105
Medford 104
Changsha 92
Ann Arbor 89
Beijing 77
Jiaxing 69
New York 67
Singapore 66
Helsinki 62
Tianjin 60
Hangzhou 52
Woodbridge 38
Shanghai 37
Milan 32
Brussels 17
Norwalk 16
Des Moines 15
Fairfield 14
Los Angeles 14
Verona 14
Auburn Hills 11
Pavia 11
Seattle 10
Toronto 10
Florence 8
Jinan 8
Kunming 8
Ningbo 8
Pune 7
Falls Church 6
Guangzhou 6
Rome 6
Taizhou 6
Tappahannock 6
Washington 6
Zhengzhou 6
Dearborn 4
Santa Clara 4
Tokyo 4
Xi'an 4
Como 3
Lanzhou 3
Nuremberg 3
Paris 3
Pognano 3
Raffadali 3
Redwood City 3
Reston 3
Saint Paul 3
Andover 2
Borås 2
Cartagena 2
Cedar Knolls 2
Dallas 2
Fuzhou 2
Genoa 2
Gießen 2
Herne 2
Istanbul 2
Kemerovo 2
Lagos 2
London 2
Manchester 2
Monmouth Junction 2
Navi Mumbai 2
Perugia 2
Peschiera Borromeo 2
Redmond 2
San Francisco 2
The Bronx 2
Ventimiglia Di Sicilia 2
Ampang 1
Amsterdam 1
Ardabil 1
Augusta 1
Baku 1
Baotou 1
Berlin 1
Bochnia 1
Brescia 1
Buffalo 1
Cairo 1
Cambridge 1
Chicago 1
Chongqing 1
Colombo 1
Dhaka 1
Dubai 1
Edmond 1
Totale 4.132
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 94
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. 93
Looking for CALR mutations in familial myeloproliferative neoplasms 87
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 82
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 79
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 79
Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug 76
Blast phase of essential thrombocythemia: A single center study. 74
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinibversusbest available therapy 74
Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders 72
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons 72
Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. 71
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 70
JAK2 (V617F) mutation in healthy individuals 70
Clinical Predictors of Outcome in MPN. 69
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. 68
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. 67
Leukemia risk models in primary myelofibrosis: an International Working Group study. 67
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process 66
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis 65
EFFICACY OF PIPOBROMAN IN THE TREATMENT OF POLYCYTHEMIA VERA: LONG TERM RESULTS IN 163 PATIENTS 65
ACUTE MYELOID LEUKEMIA (AML) HAVING EVOLVED FROM ESSENTIAL THROMBOCYTHEMIA (ET): DISTINCTIVE CHROMOSOME ABNORMALITIES IN PATIENTS TREATED WITH PIPOBROMAN OR HYDROXYUREA 65
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. 63
PDGFRB disease: right diagnosis to prolong survival 63
Looking for familial nodular lymphocyte-predominant Hodgkin lymphoma 63
EFFICACY OF A IDARUBICIN, ETOPOSIDE AND INTERMEDIATE-DOSE CYTARABINE ARABINOSIDE AS SALVAGE THERAPY IN RELAPSING OR RESISTANT UNFAVORABLE LYMPHOMA 62
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 61
Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. 61
Balancing efficacy and safety of JAK inhibitors in myelofibrosis 61
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) 61
Exaggerated insect bite-like reaction in patients affected by oncohaematological diseases 60
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 60
Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. 59
Pityriasis roseaelike eruption during treatment with imatinib mesylate: Description of 3 cases 59
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 59
New generation small-molecule inhibitors in myeloproliferative neoplasms 59
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 58
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 58
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders 58
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 58
Leucemia mieloide cronica e sindromi mieloproliferative croniche 57
A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients 57
Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. 57
TREATMENT OF EARLY STAGE HODGKIN’S DISEASE WITH FOUR CYCLES OF ABVD FOLLOWED BY ADJUVANT RADIOTHERAPY: ANALYSIS OF EFFICACY AND LONG TERM TOXICITY 56
EX VIVO MANIPULATION OF HEMATOPOIETIC STEM CELLS FOR TRANSPLANTATION: THE POTENTIAL ROLE OF AMIFOSTINE.SEMINARS IN ONCOLOGY. 55
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment 55
Pomalidomide is active in the treatment of anemia associated with myelofibrosis 55
Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders 55
Clinical relevance of JAK2 (V617F) mutant allele burden 55
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making 54
Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history 54
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera 54
Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-positive Diffuse Large B-cell Lymphomas 54
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 54
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm 53
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report 53
Myeloproliferative Neoplasms 52
Survival in young patients with intermediate-/high-risk myelofibrosis: Estimates derived from databases for non transplant patients 51
European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. 51
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 51
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. 51
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. 51
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 50
Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis 50
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 50
Direct-acting antivirals in hepatitis C virus-positive mantle cell lymphomas 50
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. 49
Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies 48
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs 48
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients 48
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. 48
Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients 48
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 48
A gain-of-function mutation of JAK2 in myeloproliferative disorders 48
Mutational status of myeloproliferative neoplasms. 47
European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. 47
Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. 47
Platelet count predicts driver mutations’ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis 47
TREATMENT OF POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA: THE ROLE OF PIPOBROMAN. 46
Ruxolitinib and survival improvement in patients with myelofibrosis 46
How to manage polycythemia vera 46
How I treat polycythemia vera. 46
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 46
Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia 45
LE NEOPLASIE MIELOPROLIFERATIVE PHILADELPHIA NEGATIVE 44
Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper 44
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment 44
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 44
RBC-transfusion guidelines update 43
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 43
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms 42
What are RBC-transfusion-dependence and -independence? 41
Primary leptomeningeal CNS lymphoma presenting as bilateral facial nerve palsy 41
Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations. 41
JAK inhibitor in CALR-mutant myelofibrosis. 41
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project 40
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas 39
It is time to change thrombosis risk assessment for PV and ET? 37
Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi 37
Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. 36
Totale 5.598
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.732
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.732
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020334 0 0 0 0 3 78 17 77 3 116 40 0
2020/2021717 99 73 13 76 7 99 5 102 28 97 96 22
2021/2022513 11 6 12 6 19 12 6 30 22 19 85 285
2022/20231.658 175 104 19 155 157 191 2 104 667 11 40 33
2023/2024604 87 104 19 52 42 171 3 36 4 12 24 50
2024/2025279 31 134 41 41 32 0 0 0 0 0 0 0
Totale 6.026